GSK Remains Positive On Medicare Rx, Outcome Of AWP Suit
GlaxoSmithKline continues to see only an upside from the potential creation of a Medicare prescription drug benefit, Pharmaceutical Operations President David Stout told investors in New York City Feb. 13
You may also be interested in...
Merck is playing a key role in the preliminary Medicare legislative drafting effort in the Senate
The Centers for Medicare & Medicaid Services will address AWP reform administratively if Congress fails to act by May, CMS Administrator Tom Scully says
Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress